Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study

  • Rangel-Zuñiga, Oriol Alberto
  • Vals-Delgado, Cristina
  • Alcala-Diaz, Juan Francisco
  • Quintana-Navarro, Gracia M.
  • Krylova, Yelizaveta
  • Leon-Acuña, Ana
  • Luque, Raul Miguel
  • Gomez-Delgado, Francisco
  • Delgado-Lista, Javier
  • Ordovas, Jose M
  • Perez-Martinez, Pablo
  • Camargo, Antonio
  • Lopez-Miranda, Jose
MicroRNAs (miRNAs) regulate the expression of genes associated with the development of diseases, including type 2 diabetes mellitus (T2DM). However, the use of miRNAs to predict T2DM remission has been poorly studied. Therefore, we aimed to investigate whether circulating miRNAs could be used to predict the probability of T2DM remission in patients with coronary heart disease. We included the newly diagnosed T2DM (n = 190) of the 1,002 patients from the CORDIOPREV study. Seventy-three patients reverted from T2DM after 5 years of dietary intervention with a low-fat or Mediterranean diet. Plasma levels of 56 miRNAs were measured by OpenArray. Generalized linear model, receiver operating characteristic (ROC), Cox regression, and pathway analyses were performed. ROC analysis based on clinical variables showed an area under the curve (AUC) of 0.66. After a linear regression analysis, seven miRNAs were identified as the most important variables in the group’s differentiation. The addition of these miRNAs to clinical variables showed an AUC of 0.79. Cox regression analysis using a T2DM remission score including miRNAs showed that high-score patients have a higher probability of T2DM remission (hazard ratio [HR]low versus high, 4.44). Finally, 26 genes involved in 10 pathways were related to the miRNAs. We have identified miRNAs (hsa-let-7b, hsa-miR-101, hsa-miR-130b-3p, hsa-miR-27a, hsa-miR-30a-5p, hsa-miR-375, and hsa-miR-486) that contribute to the prediction of T2DM remission in patients with coronary heart disease.
Repisalud
Publicación Artículo científico (JournalArticle)

HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial

  • Blanco-Rojo, Ruth
  • Perez-Martinez, Pablo
  • Lopez-Moreno, Javier
  • Martinez-Botas, Javier
  • Delgado-Lista, Javier
  • van-Ommen, Ben
  • Yubero-Serrano, Elena
  • Camargo, Antonio
  • Ordovas, Jose M
  • Perez-Jimenez, Francisco
  • Gomez-Coronado, Diego
  • Lopez-Miranda, Jose
This prospective study evaluated whether baseline cholesterol efflux is associated with future development of type 2 diabetes (T2DM) in cardiovascular patients. We measured cholesterol efflux in all CORDIOPREV study (NCT00924937) participants free of T2DM at baseline (n = 462) and assessed its relationship with T2DM incidence during a 4.5 years of follow-up. Cholesterol efflux was quantified by incubation of cholesterol-loaded THP-1 cells with the participants' apoB-depleted plasma. Disposition index was estimated as beta-cell function indicator. During follow-up 106 individuals progressed to T2DM. The cholesterol efflux/apoA-1 ratio was inversely associated with T2DM development independently of traditional risk factors (model-1, OR: 0.647, 95%CI: 0.495-0.846), and after additional adjustment for glycaemic parameters (model-2, OR: 0.670, 95%CI: 0.511-0.878). When cumulative incidence of diabetes was analysed by quartiles of cholesterol efflux/apoA-I, incidence of T2DM was reduced by 54% in subjects who were in the higher cholesterol efflux/apoA-I quartile compared to subjects in the lowest quartile (p = 0.018 and p = 0.042 for model-1 and 2). Moreover, participants who were in the higher cholesterol efflux/apoA-I presented significantly higher disposition index (β = 0.056, SE = 0.026; p = 0.035). In conclusion, HDL-cholesterol efflux normalised to apoA-I was inversely associated with T2DM development in cardiovascular patients. This association was independent of several T2DM risk factors, and may be related to a preserved beta-cell function.
Repisalud
Publicación Artículo científico (JournalArticle)

A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study

  • Jiménez-Lucena, Rosa
  • Camargo, Antonio
  • Alcala-Diaz, Juan Francisco
  • Romero-Baldonado, Cristina
  • Luque, Raul Miguel
  • van Ommen, Ben
  • Delgado-Lista, Javier
  • Ordovas, Jose M
  • Perez-Martinez, Pablo
  • Rangel-Zuñiga, Oriol Alberto
  • Lopez-Miranda, Jose
We aimed to explore whether changes in circulating levels of miRNAs according to type 2 diabetes mellitus (T2DM) or prediabetes status could be used as biomarkers to evaluate the risk of developing the disease. The study included 462 patients without T2DM at baseline from the CORDIOPREV trial. After a median follow-up of 60 months, 107 of the subjects developed T2DM, 30 developed prediabetes, 223 maintained prediabetes and 78 remained disease-free. Plasma levels of four miRNAs related to insulin signaling and beta-cell function were measured by RT-PCR. We analyzed the relationship between miRNAs levels and insulin signaling and release indexes at baseline and after the follow-up period. The risk of developing disease based on tertiles (T1-T2-T3) of baseline miRNAs levels was evaluated by COX analysis. Thus, we observed higher miR-150 and miR-30a-5p and lower miR-15a and miR-375 baseline levels in subjects with T2DM than in disease-free subjects. Patients with high miR-150 and miR-30a-5p baseline levels had lower disposition index (p = 0.047 and p = 0.007, respectively). The higher risk of disease was associated with high levels (T3) of miR-150 and miR-30a-5p (HRT3-T1 = 4.218 and HRT3-T1 = 2.527, respectively) and low levels (T1) of miR-15a and miR-375 (HRT1-T3 = 3.269 and HRT1-T3 = 1.604, respectively). In conclusion, our study showed that deregulated plasma levels of miR-150, miR-30a-5p, miR-15a, and miR-375 were observed years before the onset of T2DM and pre-DM and could be used to evaluate the risk of developing the disease, which may improve prediction and prevention among individuals at high risk for T2DM.
Repisalud
Publicación Artículo científico (JournalArticle)

MiRNAs as biomarkers of nutritional therapy to achieve T2DM remission in patients with coronary heart disease: from the CORDIOPREV study.

  • Alcala-Diaz, Juan Francisco
  • Camargo, Antonio
  • Vals-Delgado, Cristina
  • Leon-Acuña, Ana
  • Garcia-Fernandez, Helena
  • Arenas-de Larriva, Antonio P
  • Perez-Cardelo, Magdalena
  • Mora-Ortiz, Marina
  • Perez-Martinez, Pablo
  • Delgado-Lista, Javier
  • Malagon, Maria Del Mar
  • Ordovas, Jose M
  • Rangel-Zuñiga, Oriol Alberto
  • Lopez-Miranda, Jose
Type 2 diabetes mellitus (T2DM) is currently a major global public health problem. Although disease remission is possible, few biomarkers have been identified which can help us select the diet that best promotes remission. Our aim was to study the potential of miRNAs as a tool to apply the Mediterranean diet or the low-fat diet in order to achieve T2DM remission in patients with coronary heart disease. From the CORDIOPREV study (n = 1002), a prospective, randomized, single-blind, controlled dietary intervention trial, all patients newly diagnosed with T2DM (n = 190) at baseline were included in the present study. Of these, after adhering to a low fat or Mediterranean diet for 60 months, 73 patients showed T2DM remission (Responders) and 110 continued with the disease (Non-responders). Plasma levels of 56 miRNAs were determined by RT-PCR. Generalized linear model, ROC curves and COX regression analyses were performed. We observed that patients with low baseline plasma levels of miR-let7b-3p showed a high probability of T2DM remission after the consumption of a low-fat diet. In addition, patients with high levels of miR-141-5p, miR-182, and miR-192 at baseline showed a high probability of T2DM remission after following the Mediterranean diet. Scores built using miRNAs and clinical variables showed that high levels of a low-fat diet score and a high Mediterranean diet score were associated with a high probability of T2DM remission. MiRNAs could be used as a tool for selecting the most efficient nutritional therapy (mediterranean or low-fat diet) to achieve T2DM remission in patients with coronary heart disease.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Lipoprotein particle profile in the presence of peripheral artery disease among patients with coronary heart disease: Data from the CORDIOPREV study

  • Cruz Ares, Silvia de la
  • Coronado Carvajal, P.
  • Rangel Zúñiga, Oriol Alberto
  • Torres‑Peña, J.D.
  • Arenas de Larriva, Antonio P.
  • López-Moreno, Alejandro
  • Katsiki, Niki
  • Ordovás, José M.
  • Delgado-Lista, Javier
  • Pérez-Martínez, Pablo
  • Gutiérrez-Mariscal, Francisco M.
  • López-Miranda, José
BACKGROUND: Dyslipidemia is recognized as a contributing factor to peripheral artery disease (PAD). However, the influence of lipoprotein subfractions as compared to traditional serum lipid lev- els is not well-understood. Objective: This study explores the association between lipoprotein subfractions and the occurrence of PAD in patients with coronary heart disease (CHD). METHODS: In the CORDIOPREV study, 981 patients were categorized based on PAD diagnosis, determined by an ankle-brachial index (ABI) ≤0.9. Those with ABI >0.9 and <1.4 were consid- ered PAD-free, while patients with ABI ≥1.4 were excluded. We employed high-throughput nuclear magnetic resonance (NMR) spectroscopy to analyze the concentration and lipid content of lipoprotein subfractions. RESULTS: PAD patients exhibited significantly lower levels of medium high-density lipoprotein (HDL) particles and reduced concentrations of associated lipids within these subfractions except for triglycerides. A higher concentration of large or medium HDL particles correlated with a lower PAD prevalence (odds ratio [OR]: 0.61, 95% CI, 0.44-0.84; OR: 0.59, 95% CI, 0.43-0.81, respectively). In multivariate logistic regression, medium HDL particle levels inversely associated with PAD presence (OR: 0.69, 95% CI, 0.48–0.99, P = .044) after adjustment for confounding factors. CONCLUSIONS: The presence of PAD among CHD patients inversely correlates with medium HDL particle concentrations as determined by NMR. These insights could advance our understanding of PAD pathophysiology and HDL metabolism.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dietary Lipid Quantity and Quality Modulate the Postprandial Metabolomic Profile in Patients with Metabolic Syndrome

  • Mora-Ortiz, Marina
  • Yubero-Serrano, Elena María
  • Priego-Capote, Feliciano
  • Gutiérrez-Mariscal, Francisco Miguel
  • Alcalá-Díaz, Juan F.
  • Torres-Peña, José D.
  • Arenas de Larriva, Antonio Pablo
  • Delgado-Lista, Javier
  • Pérez-Martínez, Pablo
  • Roche, Helen M.
  • López-Miranda, José
16 Páginas.-- 4 Figuras, The literature on the postprandial metabolic changes in individuals with Metabolic Syndrome (MetS) remains limited, despite the fact that postprandial states represent the most common physiological condition in Western societies., The study has been supported by LIPGENE—an EU 6th Framework Program Integrated Project (FOOD-CT- 39 03-505944). The study was also co-financed by the Ministry of Economy and Competitiveness (AGL2012-39615/ALI) and the Carlos III Institute of Health, Spain (PIE14/000015/5), and by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund. CIBEROBN is an initiative of the Carlos III Institute of Health, Madrid, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial

  • Gutiérrez-Mariscal, Francisco Miguel
  • López-Moreno, Alejandro
  • Torres-Peña, José D.
  • Gómez-Luna, Purificación
  • Arenas-de Larriva, Antonio P.
  • Romero-Cabrera, Juan Luis
  • Luque, Raúl M.
  • Uribarri, Jaime
  • Pérez-Martínez, Pablo
  • Delgado-Lista, Javier
  • Yubero-Serrano, Elena María
  • López-Miranda, José
16 Páginas.-- 5 Figuras.-- 2 Tablas, Background: Increasing evidence supports the role of advanced glycation end products (AGEs) in atherosclerosis in both diabetic and non-diabetic patients, suggesting that therapeutic strategies targeting AGEs may offer potential benefits in this population. The Mediterranean diet is associated with improved biomarkers and anthropometric measurements related with atherosclerosis in addition to its ability to modulate AGE metabolism. Our aim was to determine whether the reduction in atherosclerosis progression (measured by changes in intima-media thickness of both common carotid arteries (IMT-CC)), observed after consumption of a Mediterranean diet compared to a low-fat diet, is associated with a modulation of circulating AGE levels in patients with coronary heart disease (CHD). Methods: 1002 CHD patients were divided in: (1) Non-increased IMT-CC patients, whose IMT-CC was reduced or not changed after dietary intervention and (2) Increased IMT-CC patients, whose IMT-CC was increased after dietary intervention. Serum AGE levels (methylglyoxal–MG and Nε-Carboxymethyllysine-CML) and parameters related to AGE metabolism (AGER1 and GloxI mRNA and sRAGE levels) and reduced glutathione (GSH) levels were measured before and after 5-years of dietary intervention. Results: The Mediterranean diet did not affect MG levels, whereas the low-fat diet significantly increased them compared to baseline (p = 0.029), leading to lower MG levels following the Mediterranean diet than the low-fat diet (p < 0.001). The Mediterranean diet, but not the low-fat diet, produced an upregulation of AGE metabolism, with increased AGER1 and GloxI gene expression as well as increased GSH and sRAGE levels in Non-increased IMT-CC patients (all p < 0.05). Although the Mediterranean diet increased MG levels in Increased IMT-CC patients, this increment was lower compared to the low-fat diet (all p < 0.05). Conclusions: Our results suggest that an improvement in modulation of AGE metabolism, which facilitates better management of circulating AGE levels, may be one of the mechanisms through which the Mediterranean diet, compared to a low-fat diet, reduces the progression of atherosclerosis in patients with CHD. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937, Clinicaltrials.gov number, NCT00924937. Graphical abstract: (Figure presented.)., The CORDIOPREV study was supported by the Fundación Patrimonio Comunal Olivarero(Cordioprev-CEAS, 1/2016 to Jose Lopez-Miranda). This study also received research grants from Ministerio de Ciencia e Innovación (AGL2012-39615, AGL2015-67896-P and PID2019-104362RB-I00funded by MCIN/AEI/1.0.13039/501100011033 to Jose Lopez-Miranda), from Consejería de Salud-Junta de Andalucía (PC-0283-2017 to Elena M. Yubero-Serrano) and FIS (PI18/01822 and PI21/00383 toElena M Yubero-Serrano), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. Elena M Yubero-Serrano was the recipient of the Nicolas Monardes Programme from the“Servicio Andaluz de Salud, Junta de Andalucia”, Spain (C1-0005-2019). Francisco M Gutierrez-Mariscal is supported by a CIBEROBN postdoctoral research contract. The funding bodies had no role in thestudy design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differences in splicing factors may predict type 2 diabetes remission in the CORDIOPREV study

  • Ojeda-Rodríguez, Ana
  • Torres-Peña, José D.
  • Arenas de Larriva, Antonio Pablo
  • Rangel-Zúñiga, Oriol Alberto
  • Podadera-Herreros, Alicia
  • Boughanem, Hatim
  • García, Miguel E. G.
  • López-Moreno, Alejandro
  • Katsiki, Niki
  • Luque, Raúl M.
  • Pérez-Martínez, Pablo
  • Delgado-Lista, Javier
  • Yubero-Serrano, Elena María
  • López-Miranda, José
12 Páginas.-- 4 Figuras, Alternative splicing is a post-transcriptional process resulting in multiple protein isoforms from a single gene. Abnormal splicing may lead to metabolic diseases, including type 2 diabetes mellitus (T2DM). To identify the splicing factor expression that predicts T2DM remission in coronary heart disease (CHD) patients, we identified newly diagnosed T2DM at baseline (n = 190) from the CORDIOPREV study. Patients were classified as Responders (T2DM remission during 5 years without antidiabetic drugs) or non-Responders. Baseline dysregulation in 5 splicing factors (MBNL1, RBM5, hnRNP G/RBMX, CD44, NT5E) distinguished Responders from non-Responders. Adding these factors to clinical variables [AUC = 0.67], insulin resistance, and beta-cell indexes [AUC = 0.76], improved T2DM remission prediction [AUC = 0.80]. Cox regression analysis showed those with higher remission scores had a 2.63-fold increased remission probability. To conclude, a set of splicing factors that contribute to predicting T2DM remission in patients with CHD has been identified. Further research is needed to elucidate these findings' clinical relevance., The CORDIOPREV study is supported by the Fundación Patrimonio Comunal Olivarero (Cordioprev-CEAS, 1/2016 to J.L.-M.). The main sponsor was not involved in the design or carrying out the study, and its participation was limited to funding and providing the olive oil used in the study. This study also received research grants from Ministerio de Ciencia e Innovación (AGL2012-39615, AGL2015-67896-P and PID2019-104362RB-I00 funded by MCIN/AEI/1.0.13039/501100011033 to J.L.-M.), from Consejería de Salud-Junta de Andalucía (PC-0283-2017 to E.M.Y.-S.) and FIS (PI18/01822 and PI21/00383 to E.M.Y.-S.), integrated into the framework of the National Plan for Scientific Research, Technological Development and Innovation 2013–2016, co-financed by the Instituto de Salud Carlos III (ISCIII) of Spain and also by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund (FEDER). A.O.-R. and H.B. were the recipients of Sara Borrell grants (CD21/00099 and CD22/00053, respectively) from the ISCIII. The funding bodies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank the EASP (Escuela Andaluza de Salud Publica), Granada (Spain), for carrying out the randomization process in this study. The CIBEROBN is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. The authors declare no competing interests. The authors read and approved the final manuscript., Peer reviewed